WO2011071139A1 - 有核型の口腔内崩壊錠 - Google Patents
有核型の口腔内崩壊錠 Download PDFInfo
- Publication number
- WO2011071139A1 WO2011071139A1 PCT/JP2010/072203 JP2010072203W WO2011071139A1 WO 2011071139 A1 WO2011071139 A1 WO 2011071139A1 JP 2010072203 W JP2010072203 W JP 2010072203W WO 2011071139 A1 WO2011071139 A1 WO 2011071139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- outer layer
- tablet
- inner core
- orally disintegrating
- nucleated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Definitions
- the present invention relates to a nucleated type orally disintegrating tablet.
- the inner core is a powder with low moldability, and it has an outer layer that covers the periphery of the inner core, giving it an appropriate hardness and excellent disintegration in the oral cavity as the final molded tablet
- the present invention relates to a nucleated molded product (hereinafter sometimes referred to as “nucleated orally disintegrating tablet”). That is, the present invention relates to a nucleated type orally disintegrating tablet in which an outer layer rapidly disintegrates in the oral cavity even after taking a small amount of water or without water, and thereafter granules or powders of the inner core are dispersed in the oral cavity.
- Patent Document 1 discloses a nucleated type orally disintegrating tablet as a form of a tablet that has not been known so far.
- the nucleated tablet is a tablet having a double structure of an inner core and an outer layer of the tablet, and has attracted attention as a new tablet forming technique.
- the formulation design focuses on the solubility and disintegration of the inner core, and the inner core component is composed of components having moldability as well as the outer layer component ( For example, as can be seen from the results of Test Example 2 in which a tablet was produced only with the inner core component, the inner core component has moldability and is considered to have a certain hardness or more).
- the outer layer of the nucleated molded article disclosed in Patent Document 1 has a disclosure relating to a combination of crystalline cellulose and sugar or sugar alcohol, but a combination further including a specific component in the present invention has not been disclosed.
- specific components (carmellose, low-substituted hydroxypropylcellulose, natural starch, crospovidone), which are essential components of the outer layer of the present invention, are described in Patent Document 1 as a dissolution / disintegration accelerator for the inner core (9 Page, lines 17-26).
- the outer layer includes a component having high moldability, and preferably further includes a component having high solubility and / or disintegration.
- the inner core has solubility or / And a component that is rich in disintegration, and in some cases, further contains a dissolution / disintegration accelerator ”(page 8, lines 14 to 17), thereby making the structure of the molded article a double structure of an inner core and an outer layer.
- Patent Document 1 it is considered that the feature is found by adding a component such as a dissolution / disintegration accelerator to the inner core and not adding it to the outer layer.
- the specific component is an essential component of the outer layer, and the method of using the specific component is completely opposite between the present invention and Patent Document 1.
- Patent Document 2 discloses a trial in which microcapsule-like granules are applied to the inner core component of the nucleated molded product in Patent Document 1 described above. That is, Patent Document 2 discusses the application of microcapsule-like granules to the inner core of a nucleated molded product.
- the outer layer has a composition composed of a lactose / crystalline cellulose component, and a predetermined manufacturing method is used.
- a manufacturing example in which a nucleated molded product containing a granule-like granule in the inner core is completed is disclosed.
- Patent Document 2 only discloses the invention of the nucleated molded article containing the above microcapsule-like granules in the inner core, and further studies for applying the nucleated molded article here to the orally disintegrating tablet have not been made. There was no suggestion.
- the outer layer component the component applicable as a nucleated molded product containing the microcapsule-like granule in the inner core has not been studied other than the composition from the lactose / crystalline cellulose component. The essential component combination was not disclosed. Moreover, there is no disclosure regarding the component containing mannitol in the outer layer of the nucleated molded article.
- Patent Document 3 has a disclosure regarding an orally disintegrating tablet containing mannitol, but there is no specific disclosure regarding a nucleated molded product.
- International Publication No. 2003/028706 International Publication No. 2005/097041 JP 2001-58944 A
- Orally disintegrating tablets are tablets that disintegrate rapidly in the oral cavity.
- the hardness and disintegration of tablets are in a contradictory relationship. Increasing the hardness deteriorates the disintegration, and conversely improving the disintegration decreases the hardness.
- coexistence of hardness and disintegration is a major issue.
- orally disintegrating tablets containing various functional ingredients and particles when various functional ingredients and particles are uniformly dispersed in the tablet, especially when functional ingredients and particles that adversely affect moldability are blended, In order to compensate for this, other additives need to be blended, and further contrivances have been demanded due to adverse effects such as enlargement of tablets.
- the outer layer containing the inner core has a coreless tablet (ordinary tablet) or normal It became clear in the process of completing the present invention that a higher hardness should be imparted compared to the dry-coated tablets.
- Patent Document 1 and Patent Document 2 are interesting as a new tablet technology.
- Patent Document 2 discloses a production example in which microcapsule-like granules are applied to the inner core. Furthermore, application to further functional preparations such as orally disintegrating tablets was expected.
- a nucleated tablet having an outer layer similar to the formulation disclosed in Patent Document 2 was actually produced, the disintegration property in the oral cavity was extremely poor (see Comparative Example 1-4 of the present invention).
- the outer layer disclosed in Patent Document 1 that is regarded as a nucleated fast disintegrating tablet, it was found that sufficient hardness was not obtained when a nucleated tablet containing particles having no moldability was produced (this book) (See Comparative Example 1-5 of the invention).
- the object of the present invention is to newly develop a nucleated molded product characterized in that the inner core is a granular material having a low moldability, and has an excellent disintegration property and appropriate hardness as a whole tablet. It is to provide an orally disintegrating tablet of the type.
- nucleated molded article comprising an inner core and an outer layer covering the periphery of the inner core, the inner core is composed of a granular material having low moldability, and the outer layer is made of crystalline cellulose, sugar or sugar alcohol and the specific components shown below ( It was found that a nucleated orally disintegrating tablet containing c) and having appropriate hardness and disintegration as a whole tablet can be produced.
- the ratio of the thickness of the inner core to the whole tablet is 30 to 80%
- the outer layer components are (a) crystalline cellulose, (b) sugar or sugar alcohol, and (c) crospovidone, starches,
- the outer layer components are (a) crystalline cellulose, (b) sugar or sugar alcohol, and (c) crospovidone, starches,
- the present invention provides the following various aspects of the invention.
- An orally disintegrating tablet having an outer layer covering the periphery of the inner core, wherein the ratio of the thickness of the inner core to the whole tablet is 30 to 80%, and the outer layer is (a) crystalline cellulose, (b) A nucleated orally disintegrating tablet containing sugar or sugar alcohol and (c) one or more specific components selected from the group consisting of crospovidone, starches, low-substituted hydroxypropylcellulose and carmellose.
- Nucleated orally disintegrating tablets [Item 7]
- the specific component (c) in the outer layer contains one or more selected from the group consisting of crospovidone, low-substituted hydroxypropylcellulose, and carmellose, and the total of the components in 100% by weight of the outer layer Item 6.
- [Item 10] The nucleated orally disintegrating tablet according to any one of Items 1 to 9, wherein the ratio of the thickness of the inner core to the whole tablet is 30 to 70%.
- [Item 11] The nucleated orally disintegrating tablet according to any one of Items 1 to 10, wherein the porosity of the inner core is larger than the porosity of the outer layer.
- [Item 12] The nucleated orally disintegrating tablet according to any one of Items 1 to 11, wherein the inner core contains an active ingredient.
- a cored molded product characterized in that the inner core is a granular material having low moldability, and the cored type orally disintegrating tablet having excellent disintegration property and appropriate hardness as a whole tablet Can provide.
- the nucleated type orally disintegrating tablet in the present invention is suitable for an “inner core” composed of a low-formability powder such as microcapsule-like functional particles and a final molded tablet covering the periphery of the inner core. Consists of an “outer layer” that imparts hardness and disintegration.
- an inner core component other than microcapsule-like functional particles, it is possible to carry out powders, granules, powders, etc. having low formability, and have sufficient hardness and disintegration.
- a karyotype orally disintegrating tablet is provided.
- the “outer layer” is selected from the group consisting of (a) crystalline cellulose, (b) sugar or sugar alcohol, and (c) crospovidone, starches, low-substituted hydroxypropylcellulose, and carmellose. Contains two or more specific components. By combining these components, a cored type orally disintegrating tablet that maintains sufficient hardness as a final molded product (orally disintegrating tablet) and has good disintegration can be obtained even with an inner core composed of components having low moldability. . It is preferable that the inner core is a granular material having low moldability, and when it contains 30% or more with respect to the thickness of the whole tablet, good disintegration is obtained.
- Orally disintegrating tablet means a tablet that disintegrates rapidly in the oral cavity without ingesting water to take the tablet.
- the oral disintegration time of the “orally disintegrating tablet” is measured by a disintegration test in the human oral cavity or a disintegration test by a device.
- Examples of the orally disintegrating tablet tester used in the disintegration test include model ODT-101 manufactured by Toyama Sangyo Co., Ltd.
- Oral disintegration time means a tablet in which the inner core and outer layer disintegrate or disperse usually within 60 seconds, preferably within 45 seconds, more preferably within 30 seconds, and most preferably within 20 seconds.
- the oral disintegration time includes the tablet in the human oral cavity, and the time until the tablet completely disintegrates was measured. After the test, the contents were discharged and the oral cavity was washed with clean water.
- the average particle diameter is represented by a value measured by, for example, a laser diffraction particle size measuring device (HELOS & RODOS) manufactured by SYMPATEC or a laser diffraction particle size distribution measuring device (SALD3000) manufactured by Shimadzu Corporation.
- HELOS & RODOS laser diffraction particle size measuring device
- SALD3000 laser diffraction particle size distribution measuring device
- a bulk density is represented by the value measured by the constant mass method (1st method) described in Japanese Pharmacopoeia 15th revision. That is, it means a numerical value represented by the following formula when the bulk volume when a sample of about 30 g is usually put into a 100 mL (cm 3 ) glass graduated cylinder without being compacted is X cm 3 . However, if the specimen overflows from the graduated cylinder, the weight of the specimen should be reduced as appropriate.
- Bulk density (g / cm 3 ) weight of specimen (g) ⁇ X (cm 3 )
- the tablet hardness was measured using a tablet hardness tester (PORTABLE CHECKER PC-30 manufactured by Okada Seiko Co., Ltd.) to measure the force necessary for crushing in the diameter direction.
- “Absolute hardness” was calculated by the following formula using the value of the split hardness measured by the tablet hardness tester.
- “Absolute hardness” is a value obtained by dividing the hardness measured with a tablet hardness tester by the cross-sectional area (tablet diameter (mm) ⁇ tablet thickness (mm)) obtained by dividing the tablet in the longitudinal direction by the following formula: Desired.
- Absolute hardness (N / mm 2 ) Hardness (N) / Cross sectional area (mm 2 )
- HDBI Hardness and Disintegrating Balance Index
- the porosity is calculated
- Tablet porosity (%) (1 ⁇ Wt / ( ⁇ ⁇ V)) ⁇ 100 ⁇ : True density of tablets (mg / mm 3 ), V: Tablet volume (mm 3 ), Wt: Tablet weight (mg)
- the porosity can be measured as a porosity using, for example, a pore distribution measuring device (Micromeritics) manufactured by Shimadzu Corporation.
- the porosity of the outer layer is determined by the following equation.
- Porosity of outer layer (%) (1 ⁇ Wt / ( ⁇ ⁇ 3.14 ⁇ D 2 ⁇ T)) ⁇ 100 ⁇ : true density of outer layer (mg / mm 3 ), D: radius (mm) of outer layer (lower), T: thickness of outer layer (lower) (mm), Wt: weight of outer layer (lower) (mg)
- the thickness of the inner core was calculated by the following method.
- the thickness of the whole tablet was measured with a digital caliper (Mitutoyo).
- the dry coated tablet was divided in the diameter direction, the cross section was observed with a digital microscope (VHX-500 manufactured by Keyence), and the thicknesses of the upper and lower outer layers were measured.
- Inner core thickness (mm) Total tablet thickness (mm) ⁇ Total thickness of upper and lower outer layers (mm)
- “the ratio of the thickness of the inner core” means the ratio of the thickness occupied by the inner core to the thickness of the whole tablet. That is, the ratio of the thickness which an inner core occupies in the cross section parallel to the side surface of a tablet is meant.
- Ratio of inner core thickness (%) inner core thickness (mm) ⁇ total tablet thickness (mm) ⁇ 100
- the porosity of the outer layer is usually 1 to 20%, preferably 1 to 15%.
- the porosity of the inner core is usually 10 to 90%. Preferably, it is 20 to 80%.
- the porosity of the inner core is preferably larger than the porosity of the outer layer.
- Outer layer (a) Crystalline cellulose The crystalline cellulose used as an essential component of the outer layer of this invention will not be specifically limited if oral administration is possible. When the average particle size of the crystalline cellulose is large, it feels rough after disintegrating in the oral cavity. Therefore, the average particle size of the crystalline cellulose used as a raw material is preferably 150 ⁇ m or less, more preferably 130 ⁇ m or less. Preferably it is 120 micrometers or less.
- the orally disintegrating tablet of the present invention needs to impart hardness as a whole tablet only by the outer layer.
- the blending ratio of the crystalline cellulose used in the present invention is usually 10% by weight or more when the total weight of the outer layer is 100% by weight. .
- the blending proportion of crystalline cellulose used in the present invention is usually when the total weight of the outer layer is 100% by weight. 90% by weight or less.
- the blending ratio of the crystalline cellulose is 10 to 90% by weight, preferably 20 to 70% by weight when the total weight of the outer layer is 100% by weight.
- Examples of the crystalline cellulose used in the present invention include, for example, Theolas (CEOLUS, registered trademark, PH-101, PH-102, PH-301, PH-302, PH-F20J, KG-802, KG-1000, ST-02. : Asahi Kasei Chemicals), Avicel (AVICEL, registered trademark, PH-101, PH-102, PH-301, PH-302, FD-101, FD-301, FD-F20: manufactured by FMC BioPolymer) It is done. These crystalline celluloses may be used alone or in combination of two or more.
- the bulk density of the crystalline cellulose used in the present invention is preferably 0.1 to 0.5 g / cm 3 , more preferably 0.1 to 0.3 g / cm 3 .
- Examples of crystalline cellulose having a bulk density of 0.1 to 0.3 g / cm 3 include Theorus KG-802 and KG-1000.
- sugar or sugar alcohol used as an essential component of the outer layer of the present invention is not particularly limited as long as it can be administered orally, and is naturally derived from animals or plants, or chemically synthesized. Any of those obtained by a method or a fermentation method may be used.
- the blending ratio of the sugar or sugar alcohol used in the present invention is usually 0.5 to 84% by weight when the total weight of the outer layer is 100% by weight from the viewpoint of ingestion.
- the amount is preferably 20 to 80% by weight, more preferably 20 to 75% by weight.
- the sugar include glucose, fructose, sucrose, lactose (lactose), maltose, trehalose, palatinose and the like.
- lactose and trehalose are preferable, and lactose is most preferable.
- sugar alcohols include erythritol, mannitol, xylitol, sorbitol, maltitol, etc. Among them, erythritol and mannitol are preferable, and mannitol is most preferable from the viewpoint of a balance between hardness and disintegration.
- Lactose that can be used for the outer layer of the present invention is not particularly limited as long as it can be administered orally.
- ⁇ -lactose monohydrate There are ⁇ -lactose monohydrate, ⁇ -anhydrous lactose, and ⁇ -anhydrolactose, and ⁇ -lactose monohydrate is preferable in terms of handling.
- the average particle size of lactose used as a raw material from the viewpoint of taking feeling is preferably 150 ⁇ m or less, more preferably 120 ⁇ m or less.
- the mannitol that can be used in the outer layer of the present invention is not particularly limited as long as it can be administered orally, but D-mannitol is preferable.
- the crystal form is not particularly limited, and any of ⁇ -type, ⁇ -type, and ⁇ -type may be used, or an amorphous form obtained by spray drying may be used.
- mannitol having a high spherical density as described in JP-A-11-92403 may be used.
- the average particle size of mannitol to be blended is not particularly limited, but is preferably 10 to 300 ⁇ m, more preferably 10 to 250 ⁇ m, and still more preferably 30 to 200 ⁇ m.
- it may be appropriately pulverized as necessary. For example, it can grind
- the specific component used as an essential component of the outer layer of the present invention is at least one selected from the group consisting of crospovidone, starches, low-substituted hydroxypropylcellulose, and carmellose. .
- crospovidone starches
- low-substituted hydroxypropylcellulose and carmellose.
- these specific components are contained together with crystalline cellulose and sugar or sugar alcohol, it has been found that a desired effect can be obtained.
- the crospovidone that can be used in the present invention is not particularly limited, but those that are compatible with the Japanese Pharmacopoeia are usually used.
- the average particle size is not particularly limited, but if the average particle size of the crospovidone used is large, it feels rough after disintegrating in the oral cavity.
- the thickness is 10 to 200 ⁇ m, more preferably 10 to 150 ⁇ m, still more preferably 10 to 100 ⁇ m. In order to obtain a desired particle size, it may be appropriately pulverized as necessary. Examples of the pulverization method include a method using an airflow pulverizer or a hammer type pulverizer.
- the proportion of crospovidone in the outer layer is usually 3 to 20% by weight, preferably 5 to 10% by weight per 100% by weight of the outer layer.
- starches that can be used in the present invention are starches such as corn starch (corn starch), potato starch, rice starch, wheat starch, sweet potato starch, mung bean starch, tapioca starch, and partially pregelatinized starch.
- corn starch is preferable.
- completely pregelatinized starch cannot be applied because of its poor disintegration property.
- starches may be used alone or in combination of two or more.
- the average particle size is not particularly limited, but if the average particle size is large, it feels rough after disintegrating in the oral cavity. Therefore, the average particle size as a raw material is preferably 10 to 200 ⁇ m, more preferably from the viewpoint of ingestion.
- the thickness is 10 to 100 ⁇ m, more preferably 10 to 50 ⁇ m.
- it may be appropriately pulverized as necessary.
- the pulverization method include a method using an airflow pulverizer or a hammer type pulverizer.
- the total blending ratio of starches to be blended is usually 3 to 40% by weight, preferably 20 to 40% by weight per 100% by weight of the outer layer.
- the low-substituted hydroxypropyl cellulose that can be used in the present invention is not particularly limited to the substitution ratio of the hydroxypropoxy group, and can be used as long as it is compatible with the Japanese Pharmacopoeia.
- the substitution ratio is 7.0 to 12.9%.
- the average particle size is not particularly limited, but if the average particle size of the low-substituted hydroxypropylcellulose used is large, it feels rough after disintegrating in the oral cavity.
- the average particle size of cellulose is preferably 10 to 200 ⁇ m, more preferably 10 to 150 ⁇ m, and still more preferably 10 to 100 ⁇ m.
- the pulverization method include those using an airflow pulverizer or a hammer type pulverizer.
- the blending ratio is 3 to 20% by weight, preferably 5 to 10% by weight, per 100% by weight of the outer layer.
- C-4) Carmellose (CMC) Carmellose that can be used in the present invention is not particularly limited, but those that are compatible with the Japanese Pharmacopoeia are used.
- the average particle size is not particularly limited, but if the average particle size of carmellose used is large, it feels rough after disintegrating in the oral cavity, so that the average particle size of carmellose used as a raw material is preferably 10 to
- the thickness is 200 ⁇ m, more preferably 10 to 150 ⁇ m, still more preferably 10 to 100 ⁇ m. In order to obtain a desired particle size, it may be appropriately pulverized as necessary. Examples of the pulverization method include those using an airflow pulverizer or a hammer type pulverizer.
- the blending ratio when carmellose is blended is 3 to 20% by weight, preferably 5 to 10% by weight per 100% by weight of the outer layer.
- crospovidone, starches, and low-substituted hydroxypropylcellulose are preferable from the viewpoint of ingestion. More preferred are crospovidone and starches, and more preferred are crospovidone and corn starch. Most preferred is crospovidone from the viewpoint of the balance between hardness and disintegration.
- the total mixing ratio of the specific components is usually 6 to 43% by weight, preferably 25 to 40% by weight per 100% by weight of the outer layer. %.
- the total blending ratio of the specific components is usually 6 to 20% by weight, preferably 6 to 10% by weight, per 100% by weight of the outer layer. It is.
- formulation components can be added to the outer layer of the orally disintegrating tablet of the present invention for formulation.
- the “other formulation component” used in the present invention any component may be used as long as it has no or very little influence on the hardness and disintegration time of the drug and does not hinder formulation.
- other excipients, disintegrants, binders, sweeteners, flavoring agents, stabilizers, surfactants, fluidizing agents, antistatic agents, coating agents, lubricants, coloring agents, flavoring agents Etc. are mentioned as an example.
- the compounding amount of “other formulation ingredients” is 0.01 to 25% by weight per 100% by weight of the outer layer.
- Lubricant In the present invention, it is preferable to add a lubricant to the outer layer among the above other formulation ingredients.
- the lubricant include stearic acid, metal stearate, sodium stearyl fumarate, sucrose fatty acid ester, talc, hydrogenated oil, macrogol and the like.
- the metal stearate include magnesium stearate, calcium stearate, aluminum stearate and the like.
- stearic acid or a metal salt of stearic acid, particularly magnesium stearate is preferable in terms of manufacturability. From the viewpoint of the balance between hardness and disintegration and manufacturability, sodium stearyl fumarate is preferred.
- the average particle size before formulating the lubricant is 0.5 to 50 ⁇ m, preferably 1 to 30 ⁇ m.
- the blending ratio of the lubricant is usually 0.01 to 2.5% by weight, preferably 0.01 to 2% by weight, per 100% by weight of the outer layer. More preferably, the content is 0.01 to 1% by weight.
- the lubricant may be blended using any one of an external lubrication method and an internal lubrication method.
- the inner core is not particularly limited as long as it has good oral disintegration or dispersibility. Since the outer layer component of the present invention can impart sufficient hardness as a whole tablet even when the moldability of the inner core is low, the characteristics of the present invention can be exhibited when the inner core is a “powdery powder having low moldability”.
- the term “powders with low formability” means powders with low formability, such as powders, granulated products, etc., and when a compression molding is performed, no molded product is obtained or a molded product is obtained. Even so, the hardness is intended to be extremely low.
- the size of the “powders having low formability” used in the present invention is not particularly limited, but the average particle size is usually 3 mm or less, preferably 1 mm or less, more preferably 300 ⁇ m, from the viewpoint of ingestion in the oral cavity. Hereinafter, it is most preferably 150 ⁇ m or less.
- an active ingredient in the inner core for example, functional particles of microcapsules or coated granules containing the active ingredient, active ingredient powder itself, or microcapsules containing the active ingredient, functional particles or coated granules.
- liquidity, a dispersibility, and adhesiveness to component powder are contained.
- the granulated product is obtained by fluidized bed granulation method, extrusion granulation method, dry compaction granulation method, rolling granulation method, rolling fluidized bed granulation method, high-speed stirring granulation method, crushing granulation method, etc. Can be prepared.
- the microcapsules include microcapsules in a broad sense such as microcapsules, seamless capsules, mini soft capsules, microspheres, and the like.
- coated granules include polymer-coated granules, wax-coated granules, sugar-coated granules, and the like. Furthermore, it contains granules that may be inactivated by high-pressure tableting, such as enzyme-containing granules.
- the various coated particles are granules in which granular particles are coated with a coating film, granules in which nuclei are present in granular particles, granules in which nuclei are present in granular particles, and the like. It is a coated granule intended for enteric, gastric, heat resistance, light resistance, stability or bitterness improvement.
- coating includes covering all or part of the surface of the active ingredient with a coating component.
- the apparatus for coating include general fluidized bed granulators (including rolling fluidized bed granulators, Wurster type fluidized bed granulators, etc.).
- a fluidized bed granulator for example, SPC manufactured by POWREC Co., Ltd.
- a sizing / grinding mechanism for example, screen impeller system or blade stator system
- Wurster method equipped with a forced circulation device from the side , Cross screw, lamp breaker, etc.
- combined fluidized bed granulator for example, POWREC Co., Ltd., fine particle coating and granulator SFP-01
- rotary fluidized bed granulator for example, Nara Machinery Co., Ltd. Omnitex, etc.
- a general spray dryer for example, manufactured by Okawara Seisakusho, manufactured by Okawara Chemical Co., Ltd., manufactured by Yamato Co., Ltd., manufactured by Niro Co., Ltd.
- a general spray dryer for example, manufactured by Okawara Seisakusho, manufactured by Okawara Chemical Co., Ltd., manufactured by Yamato Co., Ltd., manufactured by Niro Co., Ltd.
- Examples of core components used in the production of the functional particles include commercially available crystalline cellulose granules, sucrose / starch spherical granules, purified sucrose spherical granules, lactose / crystalline cellulose spherical granules, D-mannitol, and anhydrous calcium hydrogen phosphate. , Magnesium oxide, magnesium hydroxide and the like.
- the active ingredient used in the orally disintegrating tablet of the present invention is not particularly limited as long as it is used as a pharmaceutically active ingredient for treatment and prevention of diseases and can be administered orally.
- nourishing tonic health drug antipyretic analgesic / anti-inflammatory drug; antipsychotic drug; hypnotic sedative drug; antispasmodic drug; central nervous system drug; cerebral metabolism improving drug; Agent; Anti-ulcer agent; Gastrointestinal motility improving agent; Antacid; Antitussive expectorant; Intestinal motility inhibitor; Antiemetic agent; Respiratory agent; Bronchodilator; Antiallergic agent; Cardiotonic agent; Arrhythmic agent; Vasoconstrictor; Coronary vasodilator; Vasodilator; Peripheral vasodilator; Hyperlipidemia agent; Biliate; Chemotherapeutic agent; Diabetes complication agent; Osteoporosis agent; Antirheumatic agent; Examples include muscle relaxants; therapeutic agents for gout; anti
- the active ingredient in the present invention may be in a salt or free form as long as it is pharmaceutically acceptable. Further, it may be in the form of a solvate such as an alcohol solvate or a hydrate. Furthermore, the active ingredients listed above may be used alone or in combination of two or more.
- the amount of the active ingredient in the inner core in the present invention is not particularly limited, but is 0.1 to 100% by weight, preferably 1 to 95% by weight with respect to 100% by weight of the inner core. %.
- the “mixing ratio of the active ingredient in the inner core” in the present invention is based on the form of “pharmaceutical active ingredient” which is generally employed as a drug. That is, in the case of a drug in the form of a salt, the amount of the salt is used as a reference.
- the above-mentioned active ingredients can be added to the outer layer within a range where the hardness and disintegration time of the final molded product are not affected or extremely small.
- the nucleated orally disintegrating tablet according to the present invention can be produced using a tableting machine capable of producing a nucleated molded product.
- a nucleated orally disintegrating tablet containing a large amount of microcapsule-like functional particles in the inner core is a tableting machine for a nucleated molded article disclosed in International Publication No. 2005/097041, etc.
- Examples of the method for producing a nucleated type orally disintegrating tablet according to the present invention in a laboratory include the following.
- the above components (a) to (c) are mixed, put in a mortar corresponding to the diameter of the inner core, and gently shaken to smooth the surface of the powder (outer layer (lower)).
- an appropriate amount of a powder having low formability corresponding to the inner core is added and temporarily compressed at a relatively low pressure using a hand press.
- the above components (a) to (c) are mixed, put into a mortar corresponding to the diameter of the tablet, and temporarily compressed at a relatively low pressure using a hand press.
- a powder having low formability corresponding to the inner core is put into a mortar corresponding to the diameter of the inner core, and temporarily compressed using a hand press machine at a relatively low pressure.
- granules before tableting may be prepared by a known method. For example, after the components (a) to (c) are uniformly mixed, a nucleated molded article can be produced by the above method using the mixture.
- each of the above components (a) to (c) may be granulated before tableting, a lubricant may be added thereto, and a mixture may be used to produce a nucleated molded product by the above method.
- a part of each of the above components (a) to (c) is granulated, and the remaining components (a) to (c) and a lubricant are added thereto, and a mixture thereof is used.
- a nucleated molded article may be produced by the above method.
- the granulation method include fluidized bed granulation method, extrusion granulation method, dry compaction granulation method, rolling granulation method, rolling fluidized bed granulation method, high-speed stirring granulation method, crushing granulation method, etc. Is mentioned.
- the orally disintegrating tablet of the present invention thus obtained means that rapidly disintegrating in the oral cavity without ingesting water to take the preparation.
- the orally disintegrating tablet of the present invention means a preparation that disintegrates within about 60 seconds mainly by saliva in the oral cavity, usually within 45 seconds, preferably within 30 seconds, more preferably within 20 seconds. Collapse.
- the orally disintegrating tablet of the present invention has a sufficient hardness that does not cause chipping or cracking during production, transportation, or medical practice.
- the orally disintegrating tablet of the present invention has a double structure and is more likely to be chipped or cracked compared to a normal orally disintegrating tablet, and it is desirable that the tablet has a higher hardness.
- the orally disintegrating tablet of the present invention the absolute hardness of 2.0 N / mm 2 or more, preferably 2.5 N / mm 2 or more.
- the shape of the nucleated type orally disintegrating tablet which is the final molded product of the present invention is not particularly limited, but may be any shape such as a circular tablet, a circular R tablet, a circular corner tablet, and various deformed tablets.
- the tablet diameter is usually 5 to 16 mm, preferably 7 to 10 mm.
- the “ratio of the thickness of the inner core” is usually 30 to 80%, preferably 30 to 70%, more preferably 30 to 60%.
- the thickness of the outer layer is usually 0.5 to 2.0 mm, preferably 0.5 to 1.5 mm, and more preferably 0.5 to 1.0 mm.
- the ratio of the volume occupied by the inner core is 10 to 60%, preferably 15 to 50% when the volume of the final molded product is 100%.
- the nucleated orally disintegrating tablet of the present invention must have disintegration property in the oral cavity and hardness sufficient to maintain the shape as a preparation when handled in the manufacturing process, distribution process, medical field, etc. .
- it is characterized by containing a low-moldability powder as an inner core, so that the outer layer needs to have sufficient strength, and compared with a normal orally disintegrating tablet that is not nucleated, the outer layer Hardness is required. It is preferable to make the porosity of the outer layer smaller than usual, and sufficient hardness can be achieved.
- the porosity of the outer layer of the tablet is preferably 1 to 20%, more preferably 1 to 15%.
- mannitol, lactose, sodium stearyl fumarate, corn starch, magnesium stearate, carmellose, low-substituted hydroxypropylcellulose (L-HPC), crystalline cellulose granules, crystalline cellulose and crospovidone are as follows unless otherwise specified. I used one.
- Mannitol Peritol 50C: manufactured by ROQUETTE
- lactose hydrate Pharmatose 200M: manufactured by DMV International
- sodium stearyl fumarate probe: Kimura Sangyo
- corn starch ((XX16) W: manufactured by Nippon Shokuhin Kako)
- Magnesium stearate light, vegetable: manufactured by Taihei Chemical Industry Co., Ltd.
- carmellose Nippon Shokuhin Kako
- NS-300 manufactured by Gotoku Pharmaceutical Co., Ltd.
- low-substituted hydroxypropyl cellulose LH-21: manufactured by Shin-Etsu Chemical Co., Ltd.
- SELFIA CP- 203: Asahi Kasei Chemicals Co., Ltd., crystalline cellulose (Ceorus PH-101 or Theolus PH-301, Theolas KG-802, Theolas KG-1000: Asahi Kasei Chemicals Co., Ltd.
- Examples 1-1 to 1-5 Examination of types of specific components ⁇ Production of nucleated orally disintegrating tablets> Five formulations containing different specific components in the outer layer were prepared according to the formulation shown in Table 1-1. First, each component of the outer layer was mixed. 40 mg of this was put into a 6 mm diameter mortar and lightly vibrated to smooth the surface of the powder (outer layer (lower)). On top of that, 50 mg of crystalline cellulose particles (Selfia CP-203) was added as an inner core component, and temporarily compressed using a hand press machine (manufactured by Riken, hydraulic press machine) at a low pressure of 3 kN.
- a hand press machine manufactured by Riken, hydraulic press machine
- This temporary compression product is placed concentrically with a diameter of 8 mm so that the outer layer (lower) faces downward, and is covered with a mortar with a diameter of 8 mm, and 140 mg of the mixture of the outer layer components above the temporary compression product (outer layer (side surface + side surface + The above)) was put into a final mold to produce a nucleated orally disintegrating tablet.
- the final molded product was tableted at 15 kN in Examples 1-2 and 1-5 and at 10 kN in others.
- the hardness of the compression molded product obtained by putting 50 mg of crystalline cellulose particles (Selfia CP-203) used in the present preparation into a 6 mm diameter die and compressing with a tableting pressure of 4 kN was less than 10N. .
- the disintegration time in the oral cavity, tablet hardness and thickness were measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 1-3 were obtained.
- any one of carmellose, corn starch, L-HPC, and crospovidone was included in the outer layer as in Examples 1-1 to 1-4, the disintegration time in the oral cavity was within 30 seconds, and the absolute hardness was 2.0 N / mm 2
- the absolute hardness was 2.0 N / mm 2
- HDBI which is an index of the balance between hardness and disintegration
- each of the prescriptions was good to take and there was no crispness in the mouth.
- the porosity of the outer layer (lower) part of these preparations was measured, all were 20% or less.
- HDBI is the largest. Also, as in Example 1-5, when mannitol of Example 1-2 was replaced with lactose, the oral disintegration time was similarly within 30 seconds and the absolute hardness satisfied 2.0 N / mm 2 or more. HDBI, which is an index of the balance between hardness and disintegration, was large.
- Comparative Examples 1-1 to 1-3 When no specific component or crystalline cellulose is contained (1) In the formulation shown in Table 2-1, a preparation containing no specific component in the outer layer was produced in the same manner as in Example 1-1. Mannitol S (manufactured by Towa Kasei Co., Ltd.) was used as mannitol. The final molded products were tableted at 4 kN and 15 kN in Comparative Examples 1-1 and 1-2, and 15 kN in Comparative Example 1-3.
- the obtained tablets were measured for oral disintegration time, tablet hardness and thickness, and the absolute hardness and HDBI were calculated, and the tablet physical properties shown in Table 2-3 were obtained.
- the oral disintegration time is within 30 seconds and the absolute hardness is 2.0 N / mm 2 or more.
- the criteria were barely satisfied in Comparative Example 1-1, the other comparative examples had low absolute hardness, and HDBI, which is an index of the balance between hardness and disintegration, was small in all comparative examples and less than 0.1.
- Comparative Example 1-4 No specific component (2) (Outer layer of Patent Document 2) A formulation having the formulation similar to the production example of Patent Document 2 shown in Table 2-4 and not containing the specific component of the present invention in the outer layer was produced in the same manner as in Example 1-1. The final molded product was tableted at 10 kN. However, the tool used a small amount of magnesium stearate applied. Cellactose 80 was manufactured by MEGGLE.
- the obtained tablets were measured for oral disintegration time, tablet hardness and thickness, and the absolute hardness and HDBI were calculated, and the tablet physical properties shown in Table 2-6 were obtained. It did not disintegrate in the oral cavity.
- Comparative Example 1-5 No specific component (3) (Outer layer of Patent Document 1) A formulation having the formulation shown in Table 2-7 and not containing the specific component of the present invention in the outer layer was produced in the same manner as in Example 1-1. The final molded product was tableted at 10 kN. The outer layer formulation was set to the same blending ratio as in Test Example 6 of Patent Document 2 (erythritol 60 mg, crystalline cellulose 19.5 mg, magnesium stearate 0.5 mg).
- the obtained tablets were measured for oral disintegration time, tablet hardness and thickness, and the absolute hardness and HDBI were calculated, and the tablet physical properties shown in Table 2-9 were obtained.
- the oral disintegration time was fast, but the absolute hardness was low, less than 1 N / mm 2 , and sufficient Hardness could not be obtained. That is, it was found that the outer layer component disclosed in Patent Document 1 cannot give sufficient hardness as a whole tablet when a dry-coated tablet having particles having no moldability as an inner core is produced.
- Examples 2-1 to 2-6 and Comparative Example 2-1 Ratio of crystalline cellulose
- Table 3-1 preparations having different amounts of crystalline cellulose in the outer layer were produced in the same manner as in Example 1-1. did.
- the final molded product was tableted at 15 kN in Comparative Example 2-1 and Examples 2-1 to 2-3, 10 kN in Example 2-4, and 4 kN in Examples 2-5 to 2-6.
- the obtained tablets were measured for oral disintegration time, tablet hardness and thickness, and the absolute hardness and HDBI were calculated, and the tablet physical properties shown in Table 3-3 were obtained.
- Comparative Example 2-1 when the amount of crystalline cellulose in the outer layer was 1%, the absolute hardness was less than 2.0 N / mm 2, and HDBI, which is an index of the balance between hardness and disintegration, was small.
- the amount of crystalline cellulose in the outer layer is 10 to 90% as in Examples 2-1 to 2-6, the disintegration time in the oral cavity is within 30 seconds, and the absolute hardness satisfies 2.0 N / mm 2 or more.
- HDBI which is an index of the balance between hardness and disintegration, was large.
- the amount of crystalline cellulose in the outer layer is too much, it becomes powdery, so the amount of crystalline cellulose in the outer layer is even better when it is 70% or less, and from the viewpoint of hardness, the amount of crystalline cellulose in the outer layer is 20%.
- the absolute hardness was 2.5 N / mm 2 or more, which was even better.
- HDBI which is an index of the balance between hardness and disintegration, was the largest.
- Examples 3-1 to 3-2 and Comparative Examples 3-1 to 3-2 Ratio of specific components (crospovidone) Preparations with different amounts of crospovidone in the outer layer with the formulation shown in Table 4-1 were produced in the same manner as in Example 1-1.
- the final molded product was tableted at 15 kN in Comparative Example 3-1 and Example 3-1, 10 kN in Example 3-2, and 4 kN in Comparative Example 3-2.
- the obtained tablets were measured for oral disintegration time, tablet hardness and thickness, and the absolute hardness and HDBI were calculated, and the tablet physical properties shown in Table 4-3 were obtained.
- Example 3-1 and Example 3-2 when the amount of crospovidone in the outer layer is 5% to 20%, the oral disintegration time is within 30 seconds and the absolute hardness satisfies 2.0 N / mm 2 or more. HDBI, which is an index of the balance between hardness and disintegration, was large.
- Comparative Example 3-1 and Comparative Example 3-2 when the amount of crospovidone in the outer layer was as small as 1% or as large as 40%, HDBI, which is an index of the balance between hardness and disintegration, was small. .
- Examples 4-1 to 4-2 and Comparative Example 4-1 Ratio of specific components (corn starch) Formulations with different amounts of corn starch in the outer layer having the formulation shown in Table 5-1 were produced in the same manner as in Example 1-1. The final molded product was tableted at 10 kN in Comparative Example 4-1 and Example 4-1, and at 15 kN in Example 4-2.
- Example 4-1 to Example 4-2 when the amount of corn starch in the outer layer is 5% to 40%, the oral disintegration time is within 30 seconds, and the absolute hardness satisfies 2.0 N / mm 2 or more. HDBI, which is an index of the balance between hardness and disintegration, was large.
- Examples 5-1 to 5-4 Types of crystalline cellulose Preparations having different types of crystalline cellulose in the outer layer were prepared in the same manner as in Example 1-1 with the formulation shown in Table 6-1. The final molded product was tableted at 15 kN.
- the disintegration time in the oral cavity, tablet hardness and thickness were measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 6-3 were obtained.
- the oral disintegration time is within 30 seconds, and the absolute hardness satisfies 2.0 N / mm 2 or more.
- HDBI which is an index of gender balance, was large.
- KG-802 or KG-1000 was used for the crystalline cellulose of the outer layer, HDBI, which is an index of the balance between hardness and disintegration, was 0.2 or more, and a tablet with a favorable balance was obtained.
- Examples 6-1 to 6-3 Types of lubricants In the formulation shown in Table 7-1, preparations having different types of lubricants in the outer layer were produced in the same manner as in Example 1-1. The final molded product was tableted at 15 kN.
- the disintegration time in the oral cavity was measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 7-3 were obtained.
- the disintegration time in the oral cavity is within 30 seconds, and the absolute hardness satisfies 2.0 N / mm 2 or more.
- HDBI which is an index of disintegration balance, was large.
- Examples 7-1 to 7-5 Combined use of specific components Preparations using two or more specific components in the outer layer in the formulation shown in Table 8-1 were produced in the same manner as in Example 1-1. The final molded product was tableted at 10 kN in Examples 7-1 and 7-3 and 15 kN in the others.
- the disintegration time in the oral cavity, tablet hardness and thickness were measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 8-3 were obtained. Even when two or more specific components of the outer layer are used in combination, the disintegration time in the oral cavity is within 30 seconds, the absolute hardness satisfies 2.0 N / mm 2 or more, and HDBI, which is an index of the balance between hardness and disintegration, is large. It was.
- the porosity of the outer layer was 9% in Example 7-1 and 10% in Example 7-3.
- Examples 8-1 to 8-2 Ratio of the thickness of the inner core According to the formulation shown in Table 9-1, preparations having different ratios of the thickness of the inner core were manufactured. First, the outer layer components were mixed. Take the powder mixture of the outer layer components shown in Table 7-1 (upper) weight, put it in a mortar with the diameter of the inner core shown in Table 7-1, and gently shake the powder surface. A predetermined amount of (Selfia CP-203) was added, and temporary compression was performed at a low pressure of 3 kN using a hand press machine (manufactured by Riken, hydraulic press machine).
- This temporary compression product is placed concentrically with a diameter of 8 mm so that the outer layer faces downward, and a mortar with a diameter of 8 mm is placed over the temporary compression product to the weight of the outer layer (side surface + upper) in Table 7-1.
- the outer layer component shown was put into final molding to produce a nucleated orally disintegrating tablet.
- the final molded product was tableted at 4 kN.
- the disintegration time in the oral cavity, tablet hardness and thickness were measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 9-3 were obtained.
- the ratio of the thickness of the inner core is 32 to 54%
- the oral disintegration time is within 30 seconds
- the absolute hardness satisfies 2.0 N / mm 2 or more
- HDBI which is an index of the balance between hardness and disintegration is large. It was.
- Example 9-1 Nucleated orally disintegrating tablet containing active ingredient (1) Production of acetaminophen-containing particles (Asahi Kasei Chemicals) Acetaminophen was coated so that the coating amount was 10% to obtain acetaminophen-containing particles.
- the coating component used was Aquacoat (manufactured by Asahi Kasei Chemicals), triacetin and mannitol 100: 25: 50% by weight.
- Table 10-1 a preparation containing an active ingredient was produced in the same manner as in Example 1-1. The final molded product was tableted at 4 kN.
- the disintegration time in the oral cavity, tablet hardness and thickness were measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 10-3 were obtained.
- the oral disintegration time was within 30 seconds, the absolute hardness satisfied 2.0 N / mm 2 or more, and HDBI, which is an index of the balance between hardness and disintegration, was large. Thus, it was found that a good nucleated orally disintegrating tablet can be obtained even when the active ingredient is contained.
- a solution obtained by dissolving 2.85 g of sodium hydroxide in 67.65 g of purified water was gradually added to 705 g of methacrylic acid copolymer LD (Polykid PA-30S: manufactured by Sanyo Chemical Industries, Ltd.) and stirred ( Second liquid).
- the second liquid was added to the first liquid, suspended, and sieved through a mesh screen having an opening diameter of 177 ⁇ m to obtain a coating coating dispersion.
- the supply air temperature is maintained at 80 to 90 ° C.
- the exhaust temperature is maintained at 26 to 30 ° C.
- the spray liquid flow rate is 10 to 12 g / min
- the spray air flow rate is 80 L / min
- the spray air pressure is 0.2 to 0.
- the production was carried out at 3 MPa, a side air pressure of 0.2 to 0.25 MPa, and an air supply amount of about 0.30 to 0.55 m 3 / min.
- the spray amount of the coating coating dispersion was about 1306 g
- the coating was completed and the coating was dried until the exhaust temperature reached 42 ° C.
- the obtained particles were sieved with a sieve of 32 mesh (aperture 500 ⁇ m) to obtain drug-containing particles having an average particle diameter of about 165 ⁇ m.
- Preparations containing active ingredient-containing particles in the inner core were prepared according to the formulation shown in Table 11-1.
- the inner core mixed particles of gasmotin-containing particles and crospovidone and talc were used.
- the outer layer components were mixed. 40 mg of this was put into a 6 mm diameter mortar and lightly vibrated to smooth the surface of the powder (outer layer (lower)).
- 50 mg of mixed particles of the inner core were added and temporarily compressed at a low pressure of 3 kN using a hand press machine (manufactured by Riken, hydraulic press machine).
- This temporary compression product is placed concentrically with a diameter of 8 mm so that the outer layer (bottom) faces down, and is covered with a mortar with a diameter of 8 mm, and the outer layer component 140 mg from the top of the temporary compression product (outer layer (side surface + upper)) And finally molded to produce a nucleated orally disintegrating tablet.
- the final molded product was tableted at 4 kN.
- the obtained tablets were measured for oral disintegration time, tablet hardness and thickness, and the absolute hardness and HDBI were calculated, and the tablet physical properties shown in Table 11-3 were obtained.
- the oral disintegration time was within 30 seconds, the absolute hardness satisfied 2.0 N / mm 2 or more, and HDBI, which is an index of the balance between hardness and disintegration, was large. Thus, it was found that a good nucleated orally disintegrating tablet can be obtained even when the active ingredient is contained.
- Comparative Examples 5-1 to 5-4 Normal tablets (nuclear-free tablets) Using the outer layer formulation of Example 1-1, ordinary tablets (core-free tablets containing no inner core) were produced. First, the raw materials were uniformly mixed so as to have the blending ratio shown in Table 12-1. 230 mg of this mixed powder was tableted at a diameter of 8 mm and a tableting pressure of 4, 10, 15 and 20 kN to produce ordinary tablets.
- the disintegration time in the oral cavity, tablet hardness and thickness were measured, and the absolute hardness and HDBI were calculated.
- the tablet physical properties shown in Table 12-3 were obtained.
- the tableting pressure was 15 kN or more
- the oral disintegration time was 30 seconds or more.
- the tableting pressure was 4 kN
- the absolute hardness was less than 1.0.
- HDBI which is an index of the balance between hardness and disintegration, was 0.15 or less.
- Comparative Example 6-1 Ordinary tablet uniformly containing non-moldable particles (core-free tablet) Using the mixture of the inner core formulation and the outer layer formulation of Example 1-1, ordinary tablets in which particles having no moldability were uniformly distributed in the tablets were produced. First, the raw materials were uniformly mixed so as to have the blending ratio shown in Table 13-1. Using this mixed powder, tableting was performed at a diameter of 8 mm and a tableting pressure of 10 kN to obtain ordinary tablets. This ordinary tablet is different from the dry-coated tablet obtained in Example 1-1 in that the amount of components contained in one tablet, tablet weight, tablet diameter, The tableting pressure was produced under the same conditions.
- nucleated type orally disintegrating tablet having an inner core with low moldability, and having a good balance between hardness and disintegration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
また、本願発明の外層の必須成分である特定成分(カルメロース、低置換度ヒドロキシプロピルセルロース、天然デンプン類、クロスポビドン)は、特許文献1には内核の溶解崩壊促進剤として記載されている(9頁、17~26行)。すなわち特許文献1では、「外層には、成形性に富む成分が含まれており、好ましくは、更に、溶解性又は/及び崩壊性に富む成分を含む。一方、内核には、溶解性又は/及び崩壊性に富む成分が含まれており、場合によっては、更に、溶解崩壊促進剤を含む」(8頁、14~17行)ことによって、「成形品の構造を内核と外層の2重構造とし、強度の必要な外層だけに成形性を付与し、内核には優れた溶解・崩壊性を付与することにより、溶解・崩壊時間が極めて速く、成形性も十分な速溶解崩壊性成形品を完成」させている(5頁、5~11行、要約)。つまり、特許文献1では、溶解崩壊促進剤のような成分を内核に加え、外層には加えないことでその特長を見出していると考えられる。一方、本願発明においては、特定成分は外層の必須成分であり、特定成分の使用方法が、本願発明と特許文献1では全く逆である。
各種機能性成分・粒子を含む口腔内崩壊錠等の開発にあたっては、各種機能性成分・粒子を錠剤中に均一に分散すると、特に成形性に悪影響を及ぼす機能性成分・粒子を配合する場合、それを補う目的で他の添加剤を配合する必要があり、錠剤の大型化などの弊害も伴い、更なる工夫が求められていた。
一方、内核が成形性の低い粉粒体である有核型の錠剤では、内核はほとんど硬度を有さず、このため、内核を包含する外層には、無核の錠剤(普通錠)や通常の有核錠と比べ、より高い硬度を付与しなければならないことが、本発明を完成する過程で明らかになった。
このように、内核と外層の二重構造を有する有核型錠剤、特に内核に成形性のない粒子を用いる場合は、実質的にその外層のみで錠剤の硬度を維持する必要があり、通常の錠剤よりも強固な硬度への工夫が要求される。一方、口腔内崩壊錠に適用させる場合には、満足な速崩壊性を得るためにその硬度の低下は避けられず、内核が低い成形性の粉粒体である有核型錠剤として要求される強固な硬度と崩壊性を両立するためには、従来の口腔内崩壊錠の処方設計の考え方をそのまま適用できない状況にあった。
本発明の目的は、内核が成形性の低い粉粒体であることを特徴とする有核成型品を新たに開発することであり、錠剤全体として優れた崩壊性及び適切な硬度を有する有核型の口腔内崩壊錠を提供することにある。
[項2]内核が、成形性の低い粉粒体からなる項1に記載の有核型の口腔内崩壊錠。
[項3]該外層の空隙率が1~20%である項1又は2に記載の有核型の口腔内崩壊錠。
[項4]該内核の空隙率が10~90%である項1~3のいずれか一項に記載の有核型の口腔内崩壊錠。
[項5]外層100重量%における結晶セルロース(a)の配合割合が、10~90重量%である項1~4のいずれか一項に記載の有核型の口腔内崩壊錠。
[項6]外層の特定成分(c)がデンプン類を含有し、外層100重量%における該デンプン類の配合割合が、3~40重量%である項1~5のいずれか一項に記載の有核型の口腔内崩壊錠。
[項7]外層の特定成分(c)がクロスポビドン、低置換度ヒドロキシプロピルセルロース及びカルメロースからなる群から選択される1種又は2種以上を含有し、外層100重量%における該成分の合計の配合割合が、3~20重量%である項1~5のいずれか一項に記載の有核型の口腔内崩壊錠。
[項8]糖又は糖アルコール(b)がマンニトールを含む項1~7のいずれか一項に記載の有核型の口腔内崩壊錠。
[項9]特定成分(c)が、コーンスターチを含む項1~6又は8のいずれか一項に記載の有核型の口腔内崩壊錠。
[項10]錠剤全体の厚みに対する内核の厚みの割合が30~70%である項1~9のいずれか一項に記載の有核型の口腔内崩壊錠。
[項11]該内核の空隙率が、該外層の空隙率より大きいことを特徴とする項1~10のいずれか一項に記載の有核型の口腔内崩壊錠。
[項12]内核が活性成分を含む項1~11のいずれか一項に記載の有核型の口腔内崩壊錠。
また本発明においては、内核成分として、マイクロカプセル様の機能性粒子以外の、成形性の低い粉末、造粒物、粉粒体等についても実施可能であり、十分な硬度と崩壊性を有する有核型の口腔内崩壊錠が提供される。
かさ密度(g/cm3)=検体の重量(g)÷X(cm3)
絶対硬度(N/mm2)=硬度(N)/断面積(mm2)
HDBI(N/mm2・秒)=絶対硬度(N/mm2)÷口腔内崩壊時間(秒)
錠剤の空隙率(%)=(1-Wt/(ρ×V))×100
ρ:錠剤の真密度(mg/mm3)、V:錠剤の体積(mm3)、Wt:錠剤重量(mg)
空隙率は、例えば島津製作所製の細孔分布測定装置(マイクロメリティクス)を用いて、気孔率として測定することができる。
本発明において、外層の空隙率は、以下の式により求められる。
外層の空隙率(%)=(1-Wt/(ρ×3.14×D2×T))×100
ρ:外層の真密度(mg/mm3)、D:外層(下)の半径(mm)、T:外層(下)の厚み(mm)、Wt:外層(下)の重量(mg)
内核の厚み(mm)=錠剤全体の厚み(mm)-上下の外層の厚みの合計(mm)
本発明において「内核の厚みの割合」とは、錠剤全体の厚みに対する内核が占める厚みの割合を意味する。つまり、錠剤の側面に対して平行な断面において、内核が占める厚みの割合を意味する。切断部位によって内核が占める厚みの割合が異なる場合は、全ての断面において最も割合が大きい値を「内核の厚みの割合」と定義する。
内核の厚みの割合(%)=内核の厚み(mm)÷錠剤全体の厚み(mm)×100
(a)結晶セルロース
本発明の外層の必須成分として用いられる結晶セルロースは、経口投与が可能なものであれば特に限定されない。結晶セルロースの平均粒子径が大きいと口腔内で崩壊した後に、ザラツキを感じるため、服用感の観点において原料とする結晶セルロースの平均粒子径は150μm以下が好ましく、より好ましくは130μm以下であり、さらに好ましくは120μm以下である。
本発明の口腔内崩壊錠は、外層のみで錠剤全体としての硬度を付与する必要がある。外層の結晶セルロースの配合割合が低いと十分な硬度がでないことから、本発明に使用される結晶セルロースの配合割合は、外層の全重量を100重量%とした場合、通常10重量%以上である。一方、服用性の観点からは、結晶セルロースの割合が多すぎると、粉っぽくなるため、本発明に使用される結晶セルロースの配合割合は、外層の全重量を100重量%とした場合、通常90重量%以下である。硬度と崩壊時間のバランスを考えると、結晶セルロースの配合割合は、外層の全重量を100重量%とした場合、10~90重量%であり、好ましくは20~70重量%である。本発明で用いられる結晶セルロースとしては、例えば、セオラス(CEOLUS、登録商標、PH-101、PH-102、PH-301、PH-302、PH-F20J、KG-802、KG-1000、ST-02:旭化成ケミカルズ社製)、アビセル(AVICEL、登録商標、PH-101、PH-102、PH-301、PH-302、FD-101、FD-301、FD-F20:FMC BioPolymer社製)等が挙げられる。これらの結晶セルロースは単独で用いてもよく、2種以上を併用することもできる。
本発明で用いられる結晶セルロースのかさ密度は、好ましくは0.1~0.5g/cm3であり、より好ましくは0.1~0.3g/cm3である。かさ密度が0.1~0.3g/cm3である結晶セルロースとしては、例えば、セオラスKG-802やKG-1000等が挙げられる。
本発明の外層の必須成分として用いられる糖又は糖アルコールは、経口投与が可能なものであれば特に限定されず、動物や植物に由来する天然のもの、あるいは化学合成法や発酵法によって得られるもののいずれであってもよい。本発明に使用される糖又は糖アルコールの配合割合は、服用性の観点から、外層の全重量を100重量%とした場合、通常0.5~84重量%である。好ましくは20~80重量%であり、より好ましくは20~75重量%である。
糖の例としては、グルコース、フルクトース、スクロース、乳糖(ラクトース)、マルトース、トレハロース、パラチノースなどが挙げられ、硬度と崩壊性のバランスの観点から、乳糖、トレハロースが好ましく、乳糖が最も好ましい。糖アルコールの例としては、エリスリトール、マンニトール、キシリトール、ソルビトール、マルチトールなどが挙げられ、なかでもエリスリトール、マンニトールが好ましく、硬度と崩壊性のバランスの観点からマンニトールが最も好ましい。
本発明の外層に用いることができる乳糖は、経口投与が可能なものであれば特に限定されない。α乳糖一水和物、β無水乳糖、α無水乳糖があり、取り扱い性の面でα乳糖一水和物が好ましい。服用感の観点において原料とする乳糖の平均粒子径は150μm以下が好ましく、より好ましくは120μm以下である。
本発明の外層に用いることができるマンニトールは、経口投与が可能なものであれば特に限定されないが、D-マンニトールが好ましい。その結晶形は特に限定されず、α型、β型、δ型のいずれを用いても良いし、噴霧乾燥して得られる無晶形のものであっても良い。一方、特開平11-92403号公報に記載のような、球形の密度の高い、マンニトールを使用しても良い。配合するマンニトールの平均粒子径としては特に限定されないが、好ましくは10~300μm、より好ましくは10~250μm、さらに好ましくは30~200μmである。所望の粒子径とするため、必要に応じて適宜粉砕してもよい。例えば、気流粉砕機やハンマー式粉砕機を用いて粉砕することができる。
服用性の観点からは、糖又は糖アルコールのうち、マンニトールを用いるのが最も好ましい。これらの糖もしくは糖アルコールは、所望の製剤に応じて、単独で用いてもまたは2種以上を併用してもよい。
本発明の外層の必須成分として用いられる特定成分は、クロスポビドン、デンプン類、低置換度ヒドロキシプロピルセルロース及びカルメロースからなる群から選択される少なくとも1種であることを特徴とする。有核型の口腔内崩壊錠の場合、内核を含有しない通常の錠剤と比較して、外層の空隙率を小さくして硬度を高める必要があるため、後述の特定成分を含まない場合や特定成分以外の崩壊性を高める成分を含有する場合には、所望の効果が得られない。それに対して、これら特定成分を結晶セルロース及び糖又は糖アルコールとともに含有する場合に、所望の効果が得られることを見出したものである。
本発明に用いることができるクロスポビドンは、特に限定されないが、通常、日本薬局方に適合しているものが用いられる。その平均粒子径としては特に限定されないが、用いるクロスポビドンの平均粒子径が大きいと口腔内で崩壊した後に、ザラツキを感じるため、服用感の観点において原料とするクロスポビドンの平均粒子径は好ましくは10~200μm、より好ましくは10~150μm、さらに好ましくは10~100μmである。所望の粒子径とするため、必要に応じて適宜粉砕してもよい。粉砕方法としては例えば気流粉砕機やハンマー式粉砕機による方法が挙げられる。クロスポビドンを配合する場合の外層中の配合割合は、外層100重量%あたり、通常3~20重量%、好ましくは5~10重量%である。
本発明に用いることができるデンプン類は、コーンスターチ(トウモロコシデンプン)、バレイショデンプン、コメデンプン、コムギデンプン、甘藷デンプン、緑豆デンプン、タピオカデンプン、部分α化デンプンなどのデンプン類が挙げられるが、中でもコーンスターチが好ましい。なお、本発明においては、完全α化デンプンは崩壊性が悪いため適用できない。これらのデンプン類は単独で用いてもよく、2種以上併用することもできる。その平均粒子径としては特に限定されないが、平均粒子径が大きいと口腔内で崩壊した後に、ザラツキを感じるため、服用感の観点において原料とする平均粒子径は好ましくは10~200μm、より好ましくは10~100μm、さらに好ましくは10~50μmである。所望の粒子径とするため、必要に応じて適宜粉砕してもよい。粉砕方法としては例えば気流粉砕機やハンマー式粉砕機による方法が挙げられる。硬度及び崩壊時間の観点から、配合するデンプン類の合計の配合割合は、外層100重量%あたり通常3~40重量%であり、好ましくは20~40重量%である。
本発明に用いることができる低置換度ヒドロキシプロピルセルロースは、ヒドロキシプロポキシ基の置換割合に特に限定されることはなく、日本薬局方に適合するものであれば用いることができ、通常のヒドロキシプロポキシ基の置換割合は7.0~12.9%である。その平均粒子径としては特に限定されないが、用いる低置換度ヒドロキシプロピルセルロースの平均粒子径が大きいと口腔内で崩壊した後に、ザラツキを感じるため、服用感の観点において原料とする低置換度ヒドロキシプロピルセルロースの平均粒子径は好ましくは10~200μm、より好ましくは10~150μm、さらに好ましくは10~100μmである。所望の粒子径とするため、必要に応じて適宜粉砕してもよい。粉砕方法としては例えば気流粉砕機やハンマー式粉砕機によるものが挙げられる。低置換度ヒドロキシプロピルセルロースを配合する場合の配合割合は、外層100重量%あたり3~20重量%、好ましくは5~10重量%である。
本発明に用いることができるカルメロースは、特に限定されないが、日本薬局方に適合しているものが用いられる。その平均粒子径としては特に限定されないが、用いるカルメロースの平均粒子径が大きいと口腔内で崩壊した後に、ザラツキを感じるため、服用感の観点において原料とするカルメロースの平均粒子径は好ましくは10~200μm、より好ましくは10~150μm、さらに好ましくは10~100μmである。所望の粒子径とするため、必要に応じて適宜粉砕してもよい。粉砕方法としては例えば気流粉砕機やハンマー式粉砕機によるものが挙げられる。カルメロースを配合する場合の配合割合は、外層100重量%あたり3~20重量%、好ましくは5~10重量%である。
本発明の口腔内崩壊錠の外層には、上記の成分以外にもその他の製剤化成分を加えて製剤化することができる。本発明で用いられる「その他の製剤化成分」としては、配合しても薬剤の硬度及び崩壊時間に影響が無いか極めて少なく、製剤化するのに支障の無い成分であればいずれでもよい。例えば、他の賦形剤、崩壊剤、結合剤、甘味剤、矯味剤・矯臭剤、安定化剤、界面活性剤、流動化剤、帯電防止剤、コーティング剤、滑沢剤、着色剤、香料等がその例として挙げられる。「その他の製剤化成分」の配合量は、外層100重量%あたり0.01~25重量%である。
本発明において、上記のその他の製剤化成分の中でも外層に滑沢剤を添加することが好ましい。滑沢剤としては、例えば、ステアリン酸、ステアリン酸金属塩、フマル酸ステアリルナトリウム、ショ糖脂肪酸エステル、タルク、硬化油、マクロゴール等が挙げられる。ステアリン酸金属塩としては、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸アルミニウム等が挙げられる。滑沢剤の中で製造性の面において、ステアリン酸又はステアリン酸金属塩、特に、ステアリン酸マグネシウムが好ましい。硬度と崩壊のバランス及び製造性の観点からは、フマル酸ステアリルナトリウムが好ましい。滑沢剤を製剤化する前の平均粒子径は、0.5~50μmであり、好ましくは1~30μmである。滑沢剤の配合割合は、外層100重量%あたり通常0.01~2.5重量%であり、好ましくは0.01~2重量%である。さらに好ましくは0.01~1重量%である。本発明において該滑沢剤は、外部滑沢法及び内部滑沢法のいずれの方法を用いて配合してもよい。
本発明において、内核は口腔内崩壊性又は分散性が良好であれば特に限定されない。本発明の外層成分は、内核の成形性が低い場合にも、錠剤全体として十分な硬度を付与できることから、内核が「成形性の低い粉粒体」の場合、本発明の特徴を発揮できる。「成形性の低い粉粒体」とは、成形性の低い粉末、造粒物等を含む粉粒体を意味し、圧縮成形した際に成形物が得られないか、若しくは成形物が得られたとしても硬度が極めて低いことを意図する。具体的には、直径6mm、重量50mgを4kNで打錠した場合に、全く成形物が得られないか、若しくは成形物が得られたとしても極めて脆弱であり、硬度が10N以下の場合をいう。本発明に用いられる「成形性の低い粉粒体」の大きさは特に限定されないが、平均粒子径は通常3mm以下、口腔内での服用性の観点から、好ましくは1mm以下、さらに好ましくは300μm以下、最も好ましくは150μm以下である。本発明において、内核に活性成分を含めることが好ましく、例えば活性成分を含む微小カプセル又は被覆顆粒の機能性粒子、活性成分粉末自身、或いは活性成分を含む微小カプセル、被覆顆粒の機能性粒子又は活性成分粉末に流動性・分散性・付着性を改善する添加剤を加えた粉粒体、造粒物が含まれる。
ここで造粒物は、流動層造粒法、押出し造粒法、乾式圧密造粒法、転動造粒法、転動流動層造粒法、高速攪拌造粒法、破砕造粒法などにより調製することができる。
本発明の口腔内崩壊錠において使用される活性成分としては、医薬活性成分として疾患の治療や予防に供され、経口投与可能なものであれば特に限定されない。例えば、滋養強壮保健薬;解熱鎮痛消炎薬;抗精神病薬;催眠鎮静薬;鎮痙薬;中枢神経作用薬;脳代謝改善薬;脳循環改善薬;抗てんかん薬;交感神経興奮剤;健胃消化剤;抗潰瘍剤;消化管運動機能改善剤;制酸剤;鎮咳去痰剤;腸運動抑制薬;鎮吐剤;呼吸促進剤;気管支拡張剤;抗アレルギー剤;強心剤;不整脈用剤;利尿剤;血管収縮剤;冠血管拡張剤;血管拡張薬;末梢血管拡張薬;高脂血症用剤;利胆剤;化学療法剤;糖尿病合併症治療薬;骨粗しょう症治療剤;抗リウマチ剤;骨格筋弛緩剤;痛風治療剤;血液凝固阻止剤;抗悪性腫瘍剤等が挙げられる。本発明における活性成分は、薬学上許容される限り、塩またはフリー体の形であってもよい。また、アルコール和物等の溶媒和物、または水和物等の形であってもよい。さらに、上記に挙げた活性成分は、単独で用いても、または2種以上を組み合わせて用いてもよい。
本発明に係る有核型の口腔内崩壊錠の製造は、有核成型品を製造できる打錠機を用いて行うことができる。多量のマイクロカプセル様の機能性粒子を内核に含有する有核型の口腔内崩壊錠は、国際公開第2005/097041号等で開示される有核成型品用打錠機、又は同様に成形性の低い内核を有する有核成型品を製造できる打錠機及び打錠方法を用いて製造することができる。
かくして得られる本発明の口腔内崩壊錠は、製剤を服用するために水を摂取することなく、口腔内で速やかな崩壊性を示すものを意味する。具体的には、本発明の口腔内崩壊錠は、口腔内で主として唾液により、約60秒以内に崩壊する製剤を意味し、通常45秒以内、好ましくは30秒以内、さらに好ましくは20秒以内で崩壊する。
以下のものを使用した。
マンニトール(パーリトール50C:ROQUETTE社製)、乳糖水和物(Pharmatose 200M:DMV International社製)、フマル酸ステアリルナトリウム(プルーブ:木村産業社)、コーンスターチ((XX16)W:日本食品化工社製)、ステアリン酸マグネシウム(軽質、植物性:太平化学産業社製)、カルメロース(NS-300:五徳薬品社製)、低置換度ヒドロキシプロピルセルロース(LH-21:信越化学工業社製)、セルフィア(CP-203:旭化成ケミカルズ社製)、結晶セルロース(セオラスPH-101又はセオラスPH-301、セオラスKG-802、セオラスKG-1000:いずれも旭化成ケミカルズ社製)、クロスポビドン(コリドンCL:BASFジャパン社製又はポリプラスドンXL-10:ISP Japan社製)
<有核型の口腔内崩壊錠の製造>
表1-1に示す処方にて、外層に異なる各特定成分を含む5種類の製剤を製造した。まず、外層の各成分を混合した。これを40mgとり、直径6mmの臼に入れ軽く振動させて粉末の表面を平滑化した(外層(下))。その上に、内核成分として結晶セルロース粒(セルフィアCP-203)を50mg加えて、ハンドプレス機(理研製、油圧式プレス機)を用いて、3kNの低い圧力で仮圧縮した。この仮圧縮物を外層(下)が下方になるように直径8mm杵に同心円状に配置し、直径8mmの臼を被せて、仮圧縮物の上から上記外層成分の混合物140mg(外層(側面+上))を入れて最終成形し、有核型の口腔内崩壊錠を製造した。最終成型物は、実施例1-2と実施例1-5は15kN、その他は10kNで打錠した。なお、本製剤に使用した結晶セルロース粒(セルフィアCP-203)50mgを、別途直径6mmの杵臼に入れて、打錠圧4kNで圧縮して得られた圧縮成型物の硬度は10N未満であった。
表2-1に示す処方にて、外層に特定成分を含まない製剤を実施例1-1と同様の方法で製造した。なお、マンニトールは、マンニットS(東和化成社製)を用いた。最終成型物は、比較例1-1と比較例1-2は4kN及び15kN、比較例1-3は15kNで打錠した。
表2-4に示す特許文献2の製造例と類似する処方にて、外層に本発明の特定成分等を含まない製剤を実施例1-1と同様の方法で製造した。最終成型物は、10kNで打錠した。ただし、杵臼は少量のステアリン酸マグネシウムを塗布したものを使用した。Cellactose 80はMEGGLE社製を使用した。
表2-7に示す処方にて、外層に本発明の特定成分を含まない製剤を実施例1-1と同様の方法で製造した。最終成型物は、10kNで打錠した。外層処方は、特許文献2の試験例6(エリスリトール60mg、結晶セルロース19.5mg、ステアリン酸マグネシウム0.5mg)と同一の配合割合とした。
つまり、特許文献1で開示される外層成分は、成形性のない粒子を内核とした有核錠を作製した場合に、錠剤全体として十分な硬度を付与することができないことがわかった。
表3-1に示す処方にて、外層の結晶セルロース量が異なる製剤を実施例1-1と同様の方法で製造した。最終成型物は、比較例2-1と実施例2-1~2-3は15kN、実施例2-4は10kN、実施例2-5~2-6は4kNで打錠した。
服用性の観点から、外層の結晶セルロース量が多すぎると粉っぽくなるため、外層の結晶セルロース量は70%以下のときさらに良好であり、硬度の観点から、外層の結晶セルロース量が20%以上の場合、絶対硬度が2.5N/mm2以上になり、さらに良好であった。また、外層の結晶セルロース量が20~30%の場合、硬度と崩壊性のバランスの指標であるHDBIが最も大きかった。
表4-1に示す処方にて、外層のクロスポビドンの量が異なる製剤を実施例1-1と同様の方法で製造した。最終成型物は、比較例3-1と実施例3-1は15kN、実施例3-2は10kN、比較例3-2は4kNで打錠した。
表5-1に示す処方にて、外層のコーンスターチの量が異なる製剤を実施例1-1と同様の方法で製造した。最終成型物は、比較例4-1と実施例4-1は10kN、実施例4-2は15kNで打錠した。
表6-1に示す処方にて、外層の結晶セルロースの種類が異なる製剤を実施例1-1と同様の方法で製造した。最終成型物は15kNで打錠した。
表8-1に示す処方にて、外層の特定成分を2種以上併用した製剤を実施例1-1と同様の方法で製造した。最終成型物は、実施例7-1及び7-3は10kN、その他は15kNで打錠した。
表9-1に示す処方にて、内核の厚みの割合が異なる製剤を製造した。まず、外層成分を混合した。表7-1の外層(上)重量に示す外層成分の混合末をとり、表7-1示す内核の直径の臼に入れ軽く振動させて粉末の表面を平滑化し、その上に、結晶セルロース粒(セルフィアCP-203)を所定量加えて、ハンドプレス機(理研製、油圧式プレス機)を用いて、3kNの低い圧力で仮圧縮した。この仮圧縮物を外層が下方になるように直径8mm杵に同心円状に配置し、直径8mmの臼を被せて、仮圧縮物の上に、表7-1の外層(側面+上)重量に示す外層成分を入れて最終成形し、有核型の口腔内崩壊錠を製造した。最終成型物は4kNで打錠した。
(1)アセトアミノフェン含有粒子の製造(旭化成ケミカルズ社製)
アセトアミノフェンに被膜量10%となるように、コーティングを施し、アセトアミノフェン含有粒子とした。被膜成分は、アクアコート(旭化成ケミカルズ社製)、トリアセチン及びマンニトールが100:25:50重量%のものを使用した。表10-1に示す処方にて、活性成分を含む製剤を実施例1-1と同様の方法で製造した。最終成型物は4kNで打錠した。
精製水567gにポリソルベート80(日局ポリソルベート80(HX):日本油脂株式会社製)31.5gを加え、十分に混和させた後、タルク(林化成株式会社製)73.5g及びクロスカルメロースナトリウム(Ac-Di-Sol:FMC BioPolymer社製)52.5gを加え、十分に攪拌した(第1液)。これとは別に、水酸化ナトリウム2.85gを精製水67.65gに溶解させた溶液を、メタクリル酸コポリマーLD(ポリキッドPA-30S:三洋化成工業株式会社製)705gに徐々に加え、攪拌した(第2液)。第1液に第2液を加え懸濁させ、177μm開口径のメッシュ網で篩過し、被覆コーティング分散液とした。
実施例1-1の外層処方を用いて、普通錠(内核を含まない無核の錠剤)を製造した。まず、表12-1に示す配合割合になるように原料を均一に混合した。この混合末230mgを、直径8mm、打錠圧4、10、15及び20kNで打錠し、普通錠を製造した。
打錠圧が15kN以上では、口腔内崩壊時間が30秒以上となった。打錠圧が4kNでは、絶対硬度が1.0未満であった。また、いずれの打錠圧においても、硬度と崩壊性のバランスの指標であるHDBIが0.15以下であった。
実施例1-1の内核処方および外層処方の混合物を用いて、成形性がない粒子が錠剤中に均一に分布した普通錠を製造した。まず、表13-1に示す配合割合になるように原料を均一に混合した。この混合末を用いて、直径8mm、打錠圧10kNで打錠し、普通錠を得た。
尚、この普通錠は、実施例1-1で得た有核錠とは錠剤の構成や成形性がない粒子の分布が異なる以外は、1錠中の含有成分量、錠剤重量、錠剤径、打錠圧を同一条件にして製造した。
Claims (12)
- 内核の周辺を覆う外層を有する口腔内崩壊錠であって、錠剤全体の厚みに対する内核の厚みの割合が30~80%であり、外層が、(a)結晶セルロース、(b)糖又は糖アルコール並びに(c)クロスポビドン、デンプン類、低置換度ヒドロキシプロピルセルロース及びカルメロースからなる群から選択される1種又は2種以上の特定成分を含有する有核型の口腔内崩壊錠。
- 内核が、成形性の低い粉粒体からなる請求項1に記載の有核型の口腔内崩壊錠。
- 該外層の空隙率が1~20%である請求項1又は2に記載の有核型の口腔内崩壊錠。
- 該内核の空隙率が10~90%である請求項1~3のいずれか一項に記載の有核型の口腔内崩壊錠。
- 外層100重量%における結晶セルロース(a)の配合割合が、10~90重量%である請求項1~4のいずれか一項に記載の有核型の口腔内崩壊錠。
- 外層の特定成分(c)がデンプン類を含有し、外層100重量%における該デンプン類の配合割合が、3~40重量%である請求項1~5のいずれか一項に記載の有核型の口腔内崩壊錠。
- 外層の特定成分(c)がクロスポビドン、低置換度ヒドロキシプロピルセルロース及びカルメロースからなる群から選択される1種又は2種以上を含有し、外層100重量%における該成分の合計の配合割合が、3~20重量%である請求項1~5のいずれか一項に記載の有核型の口腔内崩壊錠。
- 糖又は糖アルコール(b)がマンニトールを含む請求項1~7のいずれか一項に記載の有核型の口腔内崩壊錠。
- 特定成分(c)が、コーンスターチを含む請求項1~6又は8のいずれか一項に記載の有核型の口腔内崩壊錠。
- 錠剤全体の厚みに対する内核の厚みの割合が30~70%である請求項1~9のいずれか一項に記載の有核型の口腔内崩壊錠。
- 該内核の空隙率が、該外層の空隙率より大きいことを特徴とする請求項1~10のいずれか一項に記載の有核型の口腔内崩壊錠。
- 内核が活性成分を含む請求項1~11のいずれか一項に記載の有核型の口腔内崩壊錠。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10836058.7A EP2510950B1 (en) | 2009-12-11 | 2010-12-10 | Dry-coated orally disintegrating tablet |
ES10836058T ES2713330T3 (es) | 2009-12-11 | 2010-12-10 | Comprimido recubierto en seco que se desintegra oralmente |
KR1020127015343A KR101907218B1 (ko) | 2009-12-11 | 2010-12-10 | 유핵형 구강내 붕해 정제 |
CN201080063719.XA CN102740893B (zh) | 2009-12-11 | 2010-12-10 | 压制包衣的口腔崩解片剂 |
JP2011545257A JP5702305B2 (ja) | 2009-12-11 | 2010-12-10 | 有核型の口腔内崩壊錠 |
US13/513,956 US9278063B2 (en) | 2009-12-11 | 2010-12-10 | Press-coated orally-disintegrating tablets |
DK10836058.7T DK2510950T3 (en) | 2009-12-11 | 2010-12-10 | DRY-COATED ORALT-DISINTEGRATING TABLE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009281216 | 2009-12-11 | ||
JP2009-281216 | 2009-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011071139A1 true WO2011071139A1 (ja) | 2011-06-16 |
Family
ID=44145682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/072203 WO2011071139A1 (ja) | 2009-12-11 | 2010-12-10 | 有核型の口腔内崩壊錠 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9278063B2 (ja) |
EP (1) | EP2510950B1 (ja) |
JP (1) | JP5702305B2 (ja) |
KR (1) | KR101907218B1 (ja) |
CN (1) | CN102740893B (ja) |
DK (1) | DK2510950T3 (ja) |
ES (1) | ES2713330T3 (ja) |
TR (1) | TR201901905T4 (ja) |
WO (1) | WO2011071139A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013147470A (ja) * | 2012-01-20 | 2013-08-01 | Nipro Corp | 口腔内崩壊錠 |
WO2014148520A1 (ja) * | 2013-03-21 | 2014-09-25 | 大正製薬株式会社 | 固形製剤 |
WO2015008825A1 (ja) | 2013-07-19 | 2015-01-22 | 株式会社三和化学研究所 | 口腔内崩壊錠 |
JP2015537013A (ja) * | 2012-11-19 | 2015-12-24 | アサンタ・アー/エス | 速崩性錠剤 |
JP2016522272A (ja) * | 2013-03-29 | 2016-07-28 | ロケット フレールRoquette Freres | 固形物の膜コーティングのための膜形成組成物 |
JP2016530329A (ja) * | 2013-09-13 | 2016-09-29 | アール.ピー.シェーラー テクノロジーズ、エルエルシー | ペレット包含錠剤 |
JP6002870B1 (ja) * | 2015-10-16 | 2016-10-05 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101352689B1 (ko) | 2012-12-31 | 2014-01-17 | (주) 에프엔지리서치 | 불연속상과 연속상으로 이루어지는 응집단위를 포함하는 마이크로그래뉼 제형 |
WO2017055183A1 (en) * | 2015-10-02 | 2017-04-06 | Dsm Ip Assets B.V. | Process for the production of compressed tablets |
TWI767923B (zh) | 2016-07-27 | 2022-06-21 | 日商澤井製藥股份有限公司 | 口腔內崩解錠添加用組成物及其製造方法以及口腔內崩解錠 |
JP6651638B2 (ja) * | 2016-09-06 | 2020-02-19 | 沢井製薬株式会社 | 口腔内崩壊錠添加用組成物 |
KR102055667B1 (ko) * | 2018-01-19 | 2019-12-13 | 김한수 | 젤리 정제형 치약 조성물 및 그 제조방법 |
EP4243633A1 (en) * | 2020-11-13 | 2023-09-20 | Sila S.P.A. | Orally dispersible compound containing an ester or salt of n-butyric acid and process for production |
CN113476417A (zh) * | 2021-08-12 | 2021-10-08 | 郑州味千生物技术有限公司 | 一种口腔崩解片掩味外层及制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03130214A (ja) | 1989-07-20 | 1991-06-04 | Dainippon Pharmaceut Co Ltd | 不快な味が遮蔽された速放性製剤 |
JPH10182436A (ja) * | 1996-10-31 | 1998-07-07 | Takeda Chem Ind Ltd | 固形医薬製剤 |
JPH1192403A (ja) | 1997-07-23 | 1999-04-06 | Freunt Ind Co Ltd | 単一物質球形粒、該球形粒を含む医薬、食品及びそれらの製造方法 |
JP2001058944A (ja) | 1999-06-18 | 2001-03-06 | Takeda Chem Ind Ltd | 速崩壊性固形製剤 |
JP2002332226A (ja) | 2001-03-07 | 2002-11-22 | Sumitomo Pharmaceut Co Ltd | 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤 |
WO2003028706A1 (fr) | 2001-09-28 | 2003-04-10 | Sanwa Kagaku Kenkyusho Co.,Ltd | Double comprime a desintegration rapide |
WO2005055989A1 (ja) | 2003-12-09 | 2005-06-23 | Dainippon Sumitomo Pharma Co., Ltd. | 薬物含有粒子および該粒子を含む固形製剤 |
WO2005097041A1 (ja) | 2004-04-09 | 2005-10-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | 有核成型品とその製造方法 |
JP2007063263A (ja) | 2005-08-01 | 2007-03-15 | Dainippon Sumitomo Pharma Co Ltd | アムロジピン含有粒子およびそれからなる口腔内崩壊錠 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
WO1998002185A1 (fr) * | 1996-07-12 | 1998-01-22 | Daiichi Pharmaceutical Co., Ltd. | Materiaux moules par compression, a desagregation rapide, et leur procede de production |
EP0839526A3 (en) | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with fast buccal disintegration or dissolution |
US7815937B2 (en) | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
EP1203580A4 (en) | 1999-06-18 | 2004-06-30 | Takeda Chemical Industries Ltd | SOLID PREPARATIONS WITH FAST DISINTEGRATION |
MXPA02012640A (es) * | 2000-06-20 | 2004-09-10 | Sanwa Kagaku Kenkyusho Co | Piezas moldeadas que tienen nucleo y metodos y aparato para fabricarlas. |
EP1302304B1 (en) | 2000-06-20 | 2011-12-14 | Sanwa Kagaku Kenkyusho Co., Ltd. | Method of producing a nucleated molded article |
CA2474835A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Immediate release dosage forms containing solid drug dispersions |
-
2010
- 2010-12-10 US US13/513,956 patent/US9278063B2/en not_active Expired - Fee Related
- 2010-12-10 JP JP2011545257A patent/JP5702305B2/ja active Active
- 2010-12-10 DK DK10836058.7T patent/DK2510950T3/en active
- 2010-12-10 CN CN201080063719.XA patent/CN102740893B/zh not_active Expired - Fee Related
- 2010-12-10 WO PCT/JP2010/072203 patent/WO2011071139A1/ja active Application Filing
- 2010-12-10 TR TR2019/01905T patent/TR201901905T4/tr unknown
- 2010-12-10 ES ES10836058T patent/ES2713330T3/es active Active
- 2010-12-10 KR KR1020127015343A patent/KR101907218B1/ko active IP Right Grant
- 2010-12-10 EP EP10836058.7A patent/EP2510950B1/en not_active Not-in-force
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03130214A (ja) | 1989-07-20 | 1991-06-04 | Dainippon Pharmaceut Co Ltd | 不快な味が遮蔽された速放性製剤 |
JPH10182436A (ja) * | 1996-10-31 | 1998-07-07 | Takeda Chem Ind Ltd | 固形医薬製剤 |
JPH1192403A (ja) | 1997-07-23 | 1999-04-06 | Freunt Ind Co Ltd | 単一物質球形粒、該球形粒を含む医薬、食品及びそれらの製造方法 |
JP2001058944A (ja) | 1999-06-18 | 2001-03-06 | Takeda Chem Ind Ltd | 速崩壊性固形製剤 |
JP2002332226A (ja) | 2001-03-07 | 2002-11-22 | Sumitomo Pharmaceut Co Ltd | 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤 |
WO2003028706A1 (fr) | 2001-09-28 | 2003-04-10 | Sanwa Kagaku Kenkyusho Co.,Ltd | Double comprime a desintegration rapide |
WO2005055989A1 (ja) | 2003-12-09 | 2005-06-23 | Dainippon Sumitomo Pharma Co., Ltd. | 薬物含有粒子および該粒子を含む固形製剤 |
WO2005097041A1 (ja) | 2004-04-09 | 2005-10-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | 有核成型品とその製造方法 |
JP2007063263A (ja) | 2005-08-01 | 2007-03-15 | Dainippon Sumitomo Pharma Co Ltd | アムロジピン含有粒子およびそれからなる口腔内崩壊錠 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2510950A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013147470A (ja) * | 2012-01-20 | 2013-08-01 | Nipro Corp | 口腔内崩壊錠 |
JP2015537013A (ja) * | 2012-11-19 | 2015-12-24 | アサンタ・アー/エス | 速崩性錠剤 |
WO2014148520A1 (ja) * | 2013-03-21 | 2014-09-25 | 大正製薬株式会社 | 固形製剤 |
JPWO2014148520A1 (ja) * | 2013-03-21 | 2017-02-16 | 大正製薬株式会社 | 固形製剤 |
JP2016522272A (ja) * | 2013-03-29 | 2016-07-28 | ロケット フレールRoquette Freres | 固形物の膜コーティングのための膜形成組成物 |
WO2015008825A1 (ja) | 2013-07-19 | 2015-01-22 | 株式会社三和化学研究所 | 口腔内崩壊錠 |
JP2016530329A (ja) * | 2013-09-13 | 2016-09-29 | アール.ピー.シェーラー テクノロジーズ、エルエルシー | ペレット包含錠剤 |
JP6002870B1 (ja) * | 2015-10-16 | 2016-10-05 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
WO2017064815A1 (ja) * | 2015-10-16 | 2017-04-20 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
Also Published As
Publication number | Publication date |
---|---|
CN102740893A (zh) | 2012-10-17 |
JPWO2011071139A1 (ja) | 2013-04-22 |
US20120237602A1 (en) | 2012-09-20 |
DK2510950T3 (en) | 2019-03-04 |
KR101907218B1 (ko) | 2018-10-11 |
CN102740893B (zh) | 2014-07-23 |
TR201901905T4 (tr) | 2019-03-21 |
JP5702305B2 (ja) | 2015-04-15 |
ES2713330T3 (es) | 2019-05-21 |
EP2510950A4 (en) | 2013-11-06 |
EP2510950A1 (en) | 2012-10-17 |
US9278063B2 (en) | 2016-03-08 |
KR20120117985A (ko) | 2012-10-25 |
EP2510950B1 (en) | 2018-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5702305B2 (ja) | 有核型の口腔内崩壊錠 | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
JP5219924B2 (ja) | ドロキシドパを含有する安定な錠剤 | |
TW201815384A (zh) | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 | |
CN108969490A (zh) | 快速分散颗粒、口腔崩解片以及方法 | |
JP7036856B2 (ja) | 口腔内崩壊錠 | |
JP2013533881A (ja) | バノキセリンを含有する医薬組成物 | |
JP5458096B2 (ja) | 有核型の口腔内崩壊錠 | |
JP5318400B2 (ja) | レボフロキサシン含有錠剤 | |
JPWO2017047586A1 (ja) | 錠剤 | |
JP6469234B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
KR20160030093A (ko) | 구강 내 붕괴정 | |
US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
WO2014148520A1 (ja) | 固形製剤 | |
JP2008189634A (ja) | 口腔内速崩錠の製造方法 | |
JP2006232680A (ja) | 錠剤用崩壊剤及びこれを用いた錠剤 | |
JP2020196697A (ja) | L−システイン配合ビタミンc高含有圧縮成形製剤 | |
JPWO2017126478A1 (ja) | 口腔内保持型崩壊性固形製剤、その製造方法、及び該製造方法に用いる粉体組成物 | |
TW201811314A (zh) | 口腔內崩解錠添加用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080063719.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10836058 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2011545257 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13513956 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127015343 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010836058 Country of ref document: EP |